杂质参考标准
The availability of new pharmaceutical products and their quality is a key value in the modern drug development industry. The crucial stages of the drug development process are the identification, quantitation, and control of pharmaceutical impurities. The quantity of unwanted compounds determines the overall safety of the final pharmaceutical product. The restrictions of the impurity content in active pharmaceutical ingredients (APIs) and drug formulations are provided in such compendia as USP, EP, BP, JP, and ChP.
Our Impurity Reference Standards Library includes 689 drug reference standards in the stock. The certificates of analysis are provided for all compounds: they include clear-cut identity and purity data validated using NMR, HPLC/MS, and/or GC/MS methods.
Related terms: Reference standard, Related compound, Impurity, Analytical standard
Highlights
Pramipexole Related Compound A
Irinotecan Related Compound B
Flumazenil Related Compound B
Timolol Related Compound F
Telmisartan Related Compound B
Olanzapine Related Compound A
Product Features
Collection of Impurity Reference Standards is a set of 689 known drug impurities for HTS/HCS programs.
The library is composed of compounds from FDA and EMA impurity classifiers.
Calculated structural diversity of the collection: 0.9.
Comprehensive documentation with structures, trivial names, synonyms, activity coefficient values, types of action on target and references to original literature.
NMR and LCMS validated purity.
All the compounds are available in stock for hit follow-up.
The library is continuously updated.
Product Details
Format: 10 - 100 µL of 10 mM DMSO stock solutions; dry powders (1 mg);
Container: 384-well microplates;
Storage: - 18 °C;
Shipping: Dry ice.
Utility
High throughput screening (HTS);
High content screening (HCS);
Cherry picking.
